Project Grant P50CA298970
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $2.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $388,616 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct prospective clinical validation of dynamic BH3 profiling as a functional biomarker for guiding treatment selection in patients with relapsed or refractory acute myeloid leukemia. The project develops and tests a novel assay that measures changes in apoptotic priming in leukemia cells after short ex vivo drug exposure. Dynamic...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $233,478 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize and target acquired resistance to menin-KMT2A inhibitors in acute myeloid leukemia. The award funds research profiling patient samples and patient-derived xenograft models to identify gain-of-function mutations in an oncogenic chromatin complex composed of menin, KMT2A, and PSIP1 proteins that confer resistance to menin...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute, National Institutes of Health, awarded a $7.482 million Cooperative Agreement to Baylor College of Medicine on September 23, 2025, under the Cancer Centers Support Grants program (CFDA 93.397) to reduce ethnic disparities in acute lymphoblastic leukemia among Latino children and adolescents by identifying biological and social determinants of health factors that drive adverse outcomes. The award funds four research projects addressing hepatotoxicity and...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $2,498,737 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify mechanisms of malignant transformation in monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) and develop therapies for early interception of progression to multiple myeloma. The award funds three integrated research projects and two supporting cores. Project 1 discovers, models,...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $110,190 on December 27, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training in basic, clinical, and prevention research aligned with the National Cancer Program. The award funds investigation of mechanisms underlying neoantigen vaccine-induced epitope spreading in cancer immunotherapy. The research dissects how tumor neoantigen vaccines prime tumor-directed T cell responses and trigger...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...